Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2025 and 2026.
-
Tight liquidity NBB
Cash and receivables cover 0 % of short-term debt in 2026; threshold 65 %.
Financials
Financial year 2026
Mediphar Invest from Geel, company number BE0449618853, closed financial year 2026 with a result of € -3,787 after tax. For that financial year Mediphar Invest recorded a gross margin of € -3,017 and equity of € 14,368. Compared with financial year 2025, the result moved from € -3,992 to € -3,787. The company made a loss. The company holds a healthy buffer. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on September 29, 2026.
€ 14,368
▼ 21% vs 2025
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -3,787
▲ 5 % less loss than in 2025
Profit after tax over the fiscal year.
€ 11
▼ 86% vs 2025
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -47,605.
Debts at end 2026
None
No bank loans on the last day of the fiscal year.
€ 872
▼ 19% vs 2025
Supplier invoices still open on the last day of the fiscal year.
| 2023 | 2024 | 2025 | 2026 | Change 2025 → 2026 | |
|---|---|---|---|---|---|
| Gross margin | € -1,230 | € -6,199 | € -3,318 | € -3,017 | ▲ € 301 |
| Profit after taxes | € -2,978 | € -8,613 | € -3,992 | € -3,787 | ▲ € 205 |
| Equity | € 30,761 | € 22,148 | € 18,156 | € 14,368 | ▼ 21% |
| Total debts | € 31,291 | € 39,825 | € 43,892 | € 47,616 | ▲ 8% |
| Cash | € 79 | € 0 | € 75 | € 11 | ▼ 86% |
| Retained profit | € -31,212 | € -39,825 | € -43,818 | € -47,605 | ▼ € 3,787 |
| Bank debt | € 0 | € 63 | € 0 | € 0 | |
| Balance sheet total | € 62,053 | € 61,973 | € 62,048 | € 61,984 |
Key figures of Mediphar Invest, fiscal years 2023 to 2026, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2027) expected before 31 October 2027.
What happened to Mediphar Invest?
What happened at Mediphar Invest in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2026: loss of € 3,787. Source: NBB ↗
- New establishment in Geel. KBO
- Kristien Vanhoucke became a director. NBB
- Jozef Frans Boeckx became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 2,978 loss in 2023 to € 3,787 loss in 2026.
Management
Behind Mediphar Invest are Kristien Vanhoucke and Jozef Frans Boeckx. Kristien Vanhoucke is also behind PHARMASSISTANCE and Oogkliniek Dr. K. Vanhoucke.
Directors
According to the 2026 annual accounts
since 1993
Jozef Frans Boeckx
Managing director
since 1993
Establishments
Establishment units
Physical locations of this company
Doornboomstraat 5
2440 Geel
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0449.618.853
- VAT number
- BE 0449.618.853
- Registered office
- Doornboomstraat 5, 2440 Geel
- Names & denominations
- Mediphar Invest
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 9 March 1993
- Peppol
- Active · Active since 26 Sept 2025